Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JAK inhibitors in the treatment of atopic dermatitis
Raj Chovatiya, Amy S. Paller
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 927-940
Open Access | Times Cited: 225

Showing 1-25 of 225 citing articles:

Novel insights into atopic dermatitis
Charles F. Schuler, Allison C. Billi, Emanual Maverakis, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 5, pp. 1145-1154
Open Access | Times Cited: 107
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
Christeen Samuel, Hannah Cornman, Anusha Kambala, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 729-749
Open Access | Times Cited: 107
Neuroimmune communication regulating pruritus in atopic dermatitis
Martin Steinhoff, Fareed Ahmad, Atul Kumar Pandey, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1875-1898
Open Access | Times Cited: 85
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 44
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
Masahiro Kamata, Yayoi Tada
JID Innovations (2023) Vol. 3, Iss. 3, pp. 100195-100195
Open Access | Times Cited: 42
Dual-Site Biomimetic Cu/Zn-MOF for Atopic Dermatitis Catalytic Therapy via Suppressing FcγR-Mediated Phagocytosis
Fang Huang, Xiangyu Lu, Le Kuai, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 5, pp. 3186-3199
Closed Access | Times Cited: 29
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
Kun Pang, Wei Wang, Jiaxin Qin, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 59
Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options
Thomas Bieber, Amy S. Paller, Kenji Kabashima, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 9, pp. 1432-1449
Open Access | Times Cited: 54
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study
Megan N. Landis, Mark Arya, Stacy Smith, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 6, pp. 878-887
Open Access | Times Cited: 47
What’s New in Topicals for Atopic Dermatitis?
Elana Kleinman, Jennifer Laborada, Lauren Metterle, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 5, pp. 595-603
Open Access | Times Cited: 42
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Tai‐Li Chen, Ling-Ling Lee, Huei‐Kai Huang, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 11, pp. 1254-1254
Open Access | Times Cited: 41
Recent advances and future prospective of topical and transdermal delivery systems
Pronalis Tapfumaneyi, Mohammad Imran, Yousuf Mohammed, et al.
Frontiers in Drug Delivery (2022) Vol. 2
Open Access | Times Cited: 38
Oral Janus kinase inhibitors for atopic dermatitis
Daniela Mikhaylov, Benjamin Ungar, Yael Renert‐Yuval, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 5, pp. 577-592
Open Access | Times Cited: 35
Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments
Karolina Makowska, Joanna Nowaczyk, Leszek Blicharz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 781-781
Open Access | Times Cited: 33
The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials
Sanghyuk Yoon, Kihun Kim, Kihyuk Shin, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1, pp. 52-61
Closed Access | Times Cited: 32
Atopic dermatitis in children and adults
Andreas Wollenberg, Thomas Werfel, Johannes Ring, et al.
Deutsches Ärzteblatt international (2023)
Open Access | Times Cited: 30
Update on Atopic Dermatitis
Caitlyn Kellogg, Jan Smogorzewski
Advances in Pediatrics (2023) Vol. 70, Iss. 1, pp. 157-170
Closed Access | Times Cited: 27
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Maria Hordinsky, Adelaide A. Hebert, Melinda Gooderham, et al.
Pediatric Dermatology (2023) Vol. 40, Iss. 6, pp. 1003-1009
Open Access | Times Cited: 24
Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond
Mehul Sharma, Narissara Suratannon, Daniel Leung, et al.
Trends in Immunology (2024) Vol. 45, Iss. 2, pp. 138-153
Open Access | Times Cited: 14
Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission
Yawen Guo, Lei Zhu, Yanting Duan, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 9
Atopic Dermatitis Itch: Scratching for an Explanation
Georgia Biazus Soares, Takashi Hashimoto, Gil Yosipovitch
Journal of Investigative Dermatology (2024) Vol. 144, Iss. 5, pp. 978-988
Closed Access | Times Cited: 8
Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives
Enza D’Auria, Cristiana Indolfi, Miriam Acunzo, et al.
Expert Review of Clinical Immunology (2025)
Closed Access | Times Cited: 1
Skin barrier defects in atopic dermatitis: From old idea to new opportunity
Takeshi Yoshida, Lisa A. Beck, Anna De Benedetto
Allergology International (2021) Vol. 71, Iss. 1, pp. 3-13
Open Access | Times Cited: 53
Potential biomarkers of atopic dermatitis
Ling Yu, Linfeng Li
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 36
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis
Patrick O. Perche, Madison K. Cook, Steven R. Feldman
Annals of Pharmacotherapy (2022) Vol. 57, Iss. 1, pp. 86-98
Closed Access | Times Cited: 34
Page 1 - Next Page

Scroll to top